bluebird bio has entered into an advance agreement to sell a Rare Paediatric Disease Priority Review Voucher, contingent upon the FDA approving the company’s BLA for lovo-cel for sickle cell disease and granting the PRV. The PDUFA date for lovo-cel is set for 20 December this year.
The negotiated sale price for the voucher is US$103 m. This is the third PRV sale in 12 months for bluebird bio. The previous sale of two other PRVs netted the company US$197 m in total.
This suggests to me that Acadia's failure to date to sell the PRV granted for trofinetide is not because of absence of demand or a fall in the market value of PRVs.
https://au.finance.yahoo.com/news/bluebird-bio-enters-advance-agreement-120000768.html
bluebird bio has entered into an advance agreement to sell a...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.63 |
Change
-1.080(6.46%) |
Mkt cap ! $1.997B | |||
| Open | High | Low | Value | Volume |
| $16.61 | $16.65 | $15.54 | $8.354M | 529.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 830 | $15.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.74 | 1484 | 2 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |